iMBP XR 03
Alternative Names: iMBP-XR-03Latest Information Update: 02 Dec 2022
At a glance
- Originator iMetabolic Biopharma
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atherosclerosis
Most Recent Events
- 24 Nov 2022 Early research in Atherosclerosis in USA (unspecified route) (iMetabolic Biopharma pipeline, November 2022)